Back to Journals » Cancer Management and Research » Volume 10

Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia

Authors Yang L, Zhou JD, Zhang TJ, Ma JC, Xiao GF, Chen Q, Deng ZQ, Lin J, Qian J, Yao DM

Received 15 July 2018

Accepted for publication 11 September 2018

Published 29 October 2018 Volume 2018:10 Pages 4999—5007

DOI https://doi.org/10.2147/CMAR.S180150

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 2

Editor who approved publication: Professor Lu-Zhe Sun


Lan Yang,1,2,* Jing-Dong Zhou,2,3,* Ting-Juan Zhang,2,3 Ji-Chun Ma,1,2 Gao-Fei Xiao,1,2 Qin Chen,1,2 Zhao-Qun Deng,1,2 Jiang Lin,1,2 Jun Qian,2,3 Dong-Ming Yao1,2

1Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China; 2The Key Laboratory of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People’s Republic of China; 3Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China

*These authors contributed equally to this work

Background and purpose: Abundant studies have shown that lncRNA PANDAR plays an oncogenic role in human solid tumors. Although abnormal expression of PANDAR has been well investigated in solid tumors, it was rarely studied in hematologic diseases. Hence, the aim of this study was to determine the PANDAR expression level and its clinical significance in patients with acute myeloid leukemia (AML).
Materials and methods: For detecting the expression level of PANDAR in 119 AML patients and 26 controls, real-time quantitative PCR was used in this study. The prognostic values were evaluated by using Kaplan–Meier analysis, Cox regression analyses, and logistic regression analysis.
Results: PANDAR was significantly overexpressed in AML and might be a promising biomarker which could distinguish AML from normal samples (P<0.001). Patients with high expression of PANDAR (PANDARhigh) were older and showed higher bone marrow blasts than patients in PANDARlow group (P=0.029 and 0.032, respectively). Significant differences between these groups were also detected regarding risk group and karyotype finding (P=0.009 and 0.041, respectively). Importantly, PANDARhigh patients presented a significant lower complete remission rate compared to PANDARlow patients (P<0.001). Furthermore, Kaplan–Meier analysis showed that PANDARhigh patients had shorter overall survival compared to PANDARlow patients observing the whole AML cohort, and also in the non-M3 group of patients (P<0.001 and P=0.005, respectively). Multivariate analysis of Cox and logistic regression analysis confirmed that high PANDAR expression was an independent unfavorable risk factor for overall survival and complete remission in both observed patient groups.
Conclusion: These results revealed that PANDAR was overexpressed in AML, and that higher PANDAR expression was associated with poor clinical outcome. Our study therefore suggests that PANDAR expression is a promising biomarker for prognostic prediction for AML.

Keywords: long noncoding RNA, PANDAR expression, acute myeloid leukemia, complete remission, overall survival 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]